Feds Eye Schedule I for Tiny Kratom Ingredient
Published Date: 7/6/2026
Notice
Summary
The government is planning to temporarily put 7-hydroxymitragynine, a chemical found in kratom, into the strictest drug category (Schedule I) if it’s above a tiny amount. This affects anyone making, selling, or using kratom products with higher levels of this chemical. People have until July 31, 2026, to share their thoughts, and this move could change how kratom products are handled and sold.
Analyzed Economic Effects
3 provisions identified: 1 benefits, 2 costs, 0 mixed.
Temporary Schedule I Placement for 7‑OH
The Department of Health and Human Services is supporting a DEA temporary order to place 7‑hydroxymitragynine (7‑OH) above a specified threshold into Schedule I of the Controlled Substances Act for up to two years. If the temporary order is issued, products or materials that meet the threshold would be treated as Schedule I substances; stakeholders have until July 31, 2026 to submit comments to the public docket (HHS‑OASH‑2026‑0232).
Numeric Thresholds That Trigger Controls
DEA's specified threshold would treat as Schedule I: (A) any Mitragyna speciosa (kratom) botanical material containing more than 0.050% 7‑hydroxymitragynine (7‑OH) on a dry weight basis; or (B) alternative articles (including synthetic products or processed extracts, concentrates, edibles, or pills) containing more than 0.050% 7‑OH by weight/volume/volume or containing more than 1.00 milligram of 7‑OH per article. Producers, processors, and sellers of kratom products that exceed these thresholds would be subject to the temporary scheduling action.
Public Comment Invitation on Threshold and Measures
OASH has opened a public docket (HHS‑OASH‑2026‑0232) and requests data and comments by July 31, 2026 on whether the identified 7‑OH threshold constitutes an imminent hazard to public safety and on possible alternative measurement expressions. Submitted comments will be provided to the Attorney General for consideration in the temporary scheduling decision.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-22812, Medicare and Medicaid Programs; Cutting Administrative Requirements for Excellence in Patient Care
CMS is proposing to cut outdated and tricky rules in Medicare and Medicaid to help doctors and nurses spend more time caring for patients instead of paperwork. These changes aim to save money, boost flexibility, and make healthcare better and easier to manage. Comments on this plan are open until January 11, 2027, so everyone affected can share their thoughts!
2026-22792, Medicare Drug Price Negotiation Program and Medicare Prescription Drug Benefit Program
Starting in 2029, Medicare will negotiate drug prices to help lower costs for people using Medicare Part D. This new rule, effective December 5, 2026, sets clear policies to make prescription drugs more affordable and fair. If you or a loved one uses Medicare for prescriptions, expect some savings and changes in how drug prices are set.
2026-22750, Calendar Year 2027 Home Health Prospective Payment System (HH PPS) Rate Update; Requirements for the HH Quality Reporting Program and the Expanded HH Value-Based Purchasing Model; Medicare Provider Enrollment, Durable Medical Equipment (DME), and DME, Prosthetics, Orthotics, and Supplies (DMEPOS) Policies
Starting in 2027, Medicare is updating how it pays home health agencies, including new payment rates and rules to make care better and fairer. Home health providers, equipment suppliers, and Medicare enrollees will see changes in payment methods, quality reporting, and equipment rules, with some new deadlines and expanded benefits. These updates aim to improve care quality while keeping payments clear and fair.
2026-22743, Medicare and Medicaid Programs; CY 2027 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; and Medicare Prescription Drug Inflation Rebate Program
Starting January 1, 2027, Medicare and Medicaid are updating how doctors and clinics get paid to better match real medical work and new laws. This includes new rules for drug price rebates, sharing savings programs, and payment updates for rural clinics and ambulance services. These changes affect doctors, patients, and healthcare providers, aiming to keep care fair, affordable, and up-to-date.
2026-22739, Medicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems; and Quality Reporting Programs; including the Hospital Outpatient Quality Reporting Program and Ambulatory Surgical Center Quality Program; Request for Information on Strengthening the Standardization and Comparability of Hospital Price Transparency (HPT) Data; Prior Authorization; Accrediting Organization (AO) Deeming for Emergency Medical Treatment and Labor Act (EMTALA); and Notices of Closure of Teaching Hospitals and Opportunities To Apply for Available Slots
Starting in 2027, Medicare is updating how hospitals and surgery centers get paid for outpatient care and surgeries. These changes affect hospitals, surgery centers, and patients by adjusting payment rates and improving quality reporting. Plus, CMS is asking for ideas to make hospital price info clearer and easier to compare, while also handling rules about emergency care and teaching hospital closures.
2026-22381, Medicare and Medicaid Programs; Organ Procurement Organizations Conditions for Coverage: Revisions to the Conditions for Coverage
This new rule updates how Organ Procurement Organizations (OPOs) operate to help get more life-saving organs to people who need transplants. It changes some definitions, competition rules, and appeal processes to make OPOs work better and be held accountable. These changes start January 4, 2027, and aim to save more lives without adding extra costs.
Previous / Next Documents
Previous: 2026-13607, Certain Corrosion-Resistant Steel Products From the People's Republic of China: Initiation of Circumvention Inquiry on the Antidumping and Countervailing Duty Orders
The U.S. Department of Commerce is checking if certain corrosion-resistant steel products made in China but finished in Thailand are sneaking around existing trade rules. This affects steel companies like Nucor and Steel Dynamics, who want these products to face the same duties as Chinese steel. Starting July 6, 2026, this inquiry could lead to new duties and impact steel prices and imports.
Next: 2026-13610, Diamond Sawblades and Parts Thereof From China; Scheduling of an Expedited Five-Year Review
The U.S. International Trade Commission is speeding up a review to decide if special taxes on diamond sawblades and parts from China should stay or go. This affects U.S. businesses that make or sell these sawblades and could impact prices or imports soon. The review started because U.S. companies showed strong interest, while Chinese exporters didn’t respond enough.